TY - JOUR
T1 - Colitis and Crohn’s Foundation (India)
T2 - a first nationwide inflammatory bowel disease registry
AU - Sood, Ajit
AU - Kaur, Kirandeep
AU - Mahajan, Ramit
AU - Midha, Vandana
AU - Singh, Arshdeep
AU - Sharma, Sarit
AU - Puri, Amarender Singh
AU - Goswami, Bhabhadev
AU - Desai, Devendra
AU - Pai, C. Ganesh
AU - Peddi, Kiran
AU - Philip, Mathew
AU - Kochhar, Rakesh
AU - Nijhawan, Sandeep
AU - Bhatia, Shobna
AU - Rao, N. Sridhara
N1 - Funding Information:
The authors received no financial support for the research, authorship, and/or publication of this article
Publisher Copyright:
© 2021. Korean Association for the Study of Intestinal Diseases. All rights reserved.
PY - 2021/4
Y1 - 2021/4
N2 - The national registry for inflammatory bowel disease (IBD) was designed to study epidemiology and prescribing pattern of treatment of IBD in India. Methods: A multicenter, cross-sectional, prospective registry was established across four geographical zones of India. Adult patients with ulcerative colitis (UC) or Crohn’s disease (CD) were enrolled between January 2014 and December 2015. Information related to demographics; disease features; complications; and treatment history were collected and analyzed. Results: A total of 3,863 patients (mean age, 36.7±13.6 years; 3,232 UC [83.7%] and 631 CD [16.3%]) were enrolled. The majority of patients with UC (n=1,870, 57.9%) were from north, CD was more common in south (n=348, 55.5%). The UC:CD ratio was 5.1:1. There was a male predominance (male:female=1.6:1). The commonest presentation of UC was moderately severe (n=1,939, 60%) and E2 disease (n=1,895, 58.6%). Patients with CD most commonly presented with ileocolonic (n=229, 36.3%) inflammatory (n=504, 79.9%) disease. Extraintestinal manifestations were recorded among 13% and 20% of patients in UC and CD respectively. Less than 1% patients from both cohorts developed colon cancer (n=26, 0.7%). The commonly used drugs were 5-aminosalicylates (99%) in both UC and CD followed by azathioprine (34.4%). Biologics were used in only 1.5% of patients; more commonly for UC in north and CD in south. Conclusions: The national IBD registry brings out diversities in the 4 geographical zones of India. This will help in aiding research on IBD and improving quality of patient care. (Intest Res 2021;19:206-216)
AB - The national registry for inflammatory bowel disease (IBD) was designed to study epidemiology and prescribing pattern of treatment of IBD in India. Methods: A multicenter, cross-sectional, prospective registry was established across four geographical zones of India. Adult patients with ulcerative colitis (UC) or Crohn’s disease (CD) were enrolled between January 2014 and December 2015. Information related to demographics; disease features; complications; and treatment history were collected and analyzed. Results: A total of 3,863 patients (mean age, 36.7±13.6 years; 3,232 UC [83.7%] and 631 CD [16.3%]) were enrolled. The majority of patients with UC (n=1,870, 57.9%) were from north, CD was more common in south (n=348, 55.5%). The UC:CD ratio was 5.1:1. There was a male predominance (male:female=1.6:1). The commonest presentation of UC was moderately severe (n=1,939, 60%) and E2 disease (n=1,895, 58.6%). Patients with CD most commonly presented with ileocolonic (n=229, 36.3%) inflammatory (n=504, 79.9%) disease. Extraintestinal manifestations were recorded among 13% and 20% of patients in UC and CD respectively. Less than 1% patients from both cohorts developed colon cancer (n=26, 0.7%). The commonly used drugs were 5-aminosalicylates (99%) in both UC and CD followed by azathioprine (34.4%). Biologics were used in only 1.5% of patients; more commonly for UC in north and CD in south. Conclusions: The national IBD registry brings out diversities in the 4 geographical zones of India. This will help in aiding research on IBD and improving quality of patient care. (Intest Res 2021;19:206-216)
UR - http://www.scopus.com/inward/record.url?scp=85105791366&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105791366&partnerID=8YFLogxK
U2 - 10.5217/ir.2019.09169
DO - 10.5217/ir.2019.09169
M3 - Article
AN - SCOPUS:85105791366
SN - 1598-9100
VL - 19
SP - 206
EP - 216
JO - Intestinal Research
JF - Intestinal Research
IS - 2
ER -
